Abstract
The multifaceted illness known as a chronic obstructive pulmonary disease (COPD) is characterized by a decline in post-bronchodilator pulmonary function in all individuals and is linked to local and systemic inflammation, attracting alveolar macrophages (AM). The objective of this study was to use carubinose-linked hydrocortisone-hybrid nanoparticles (HC-HNPs) to increase the glycotargeting effectiveness to AM. The emulsification solvent evaporation method was used to generate the HC-HCNPs, and various analytical techniques were used to characterize them, including %entrapment efficiency, analytical characterization and histopathology examinations. Results revealed that HC is entrapped inside the hybrid preparations, which contain specific signatures of molecules that interact with ligands and are expressed all through the cell surface, as well as the amorphous nature of HC-HNPs. Field emission scanning electron microscopy (FESEM) revealed the surface structure and the particle size diameter which is enough to reach the AM through the nasal route. The high-performance liquid chromatography (HPLC) showed no interference from excipients in determining HC, indicating that the method is specific. The in-vivo findings showed that HC-HNPs demonstrated proof that very small and cost-effective nanoparticles can be developed to effectively target AM by effectively delivering HC-HNPs to the lungs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
